Last reviewed 2026-05-22 · How we verify

Eupneron (EPROZINOL)

Phase 2 active Small molecule ✓ Verified May 2026

Eupneron (generic name: EPROZINOL) is a eprozinol drug. It is currently in Phase 2 development.

Eprozinol is thought to work by inhibiting a specific enzyme or receptor, but the exact details of its mechanism are not well understood.

Eprozinol is a small molecule drug of the eprozinol class, but specific details about its target and mechanism of action are unknown. It is not clear if it has been approved by the FDA or if it is commercially available. Eprozinol's indications, half-life, bioavailability, and generic manufacturers are also unknown. As a result, there is limited information available about this compound. Further research is needed to understand its clinical utility and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	EPROZINOL
Drug class	eprozinol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and enzymes or receptors are like keys that fit into those locks. Eprozinol is like a key that blocks the action of another key, preventing it from unlocking the cell and causing a problem. This can help to reduce inflammation and other symptoms associated with certain diseases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eupneron CI brief — competitive landscape report
Eupneron updates RSS · CI watch RSS

Frequently asked questions about Eupneron

What is Eupneron?

Eupneron (EPROZINOL) is a eprozinol drug.

How does Eupneron work?

Eprozinol is thought to work by inhibiting a specific enzyme or receptor, but the exact details of its mechanism are not well understood.

What is the generic name of Eupneron?

EPROZINOL is the generic (nonproprietary) name of Eupneron.

What drug class is Eupneron in?

Eupneron belongs to the eprozinol class. See all eprozinol drugs at /class/eprozinol.

What development phase is Eupneron in?

Eupneron is in Phase 2.

Drug class: All eprozinol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing